Clinical Trial Glossary
50+ terms explained in plain language for patients and caregivers. Clinical trials come with a lot of jargon. Here is every term you might encounter.
What is a clinical trial glossary?
A clinical trial glossary is a reference guide that explains the specialized medical and scientific terminology used in clinical trial research. Understanding these terms is essential for patients and caregivers who want to make informed decisions about participating in clinical trials or evaluating trial results for their condition. This glossary covers the most common terms found in trial descriptions on ClinicalTrials.gov, medical journal publications, and research briefings. Each definition is written in plain English, avoiding unnecessary jargon, and includes practical context showing how the term applies to real patient situations. Whether you are reading a clinical trial listing for the first time or reviewing results from a Phase 3 study, this glossary gives you the vocabulary to understand what you are reading.
- Adverse Event (AE)
- Any undesirable medical event that occurs during a trial, whether or not it is caused by the treatment. Includes side effects, injuries, and unexpected symptoms.
- Biomarker
- A measurable biological indicator used to track the progress of a disease or the effect of a treatment. Examples include blood sugar levels, tumor size, or specific proteins in blood.
- Blinding (Masking)
- A method where participants, researchers, or both do not know which treatment a participant is receiving. This reduces bias in measuring outcomes.
- Clinical Endpoint
- A specific, measurable outcome that a trial uses to determine whether a treatment works. Examples include survival time, symptom improvement, or disease progression.
- Control Group
- The group of participants who receive the standard treatment or a placebo instead of the experimental treatment. Results from the treatment group are compared against this group.
- Double-Blind
- A trial where neither the participants nor the researchers know who is receiving the treatment and who is receiving the placebo. The gold standard for reducing bias.
- Efficacy
- How well a treatment works under ideal, controlled conditions in a clinical trial. Distinct from effectiveness, which measures performance in real-world settings.
- Eligibility Criteria
- The requirements that determine who can participate in a trial. Includes inclusion criteria (characteristics you must have) and exclusion criteria (characteristics that disqualify you).
- FDA (Food and Drug Administration)
- The U.S. government agency responsible for approving new drugs and treatments. Equivalent agencies exist in other countries (EMA in Europe, MHRA in the UK).
- Hazard Ratio (HR)
- A statistical measure comparing the rate of an event between the treatment group and the control group. HR of 0.75 means 25% less risk in the treatment group.
- Informed Consent
- The process of fully explaining a trial to a potential participant so they can make a voluntary, knowledgeable decision about whether to join.
- NNT (Number Needed to Treat)
- The number of patients who need to receive a treatment for one additional patient to benefit. Lower NNT means more effective. NNT of 5 is generally considered good.
- Phase 1
- The first stage of human testing. Tests safety and dosage in 20-100 people. About 70% of treatments pass Phase 1.
- Phase 2
- Tests whether the treatment works for the intended condition in 100-300 people. About 33% of treatments pass Phase 2.
- Phase 3
- Large-scale testing in 1,000-3,000+ patients across multiple sites. Compares new treatment to standard of care. Required for regulatory approval. About 58% pass.
- Phase 4
- Post-approval studies that monitor long-term effects, optimal dosing, and effectiveness in broader populations after a treatment is already available.
- Placebo
- An inactive treatment given to the control group. Allows researchers to measure whether the experimental treatment works better than no treatment.
- p-value
- A statistical measure indicating the probability that the observed result happened by chance. Below 0.05 is generally considered statistically significant.
- Randomization
- The process of randomly assigning participants to different treatment groups. Ensures groups are comparable and results are not biased by patient selection.
- Standard of Care
- The currently accepted best treatment for a condition. New treatments in clinical trials are often compared against the standard of care to see if they offer improvement.
- Statistical Significance
- A result is statistically significant when it is unlikely to have occurred by chance (typically p < 0.05). Does not necessarily mean the result is clinically meaningful.
Don't want to decode this yourself? Start monitoring your condition and get plain-language briefings.